Show simple item record

dc.contributor.authorDorey, Nicole
dc.date.accessioned2020-02-13T10:05:23Z
dc.date.available2020-02-13T10:05:23Z
dc.date.issued2020-02
dc.identifier.citationOwens R [et al]. Outcome of weekly carboplatin-paclitaxel-based definitive chemoradiation in oesophageal cancer in patients not considered to be suitable for platinum-fluoropyrimidine-based treatment: a multicentre, retrospective review. Clinical Oncology. 2020 32(2) 121-130en_US
dc.identifier.pmid31662220
dc.identifier.doi10.1016/j.clon.2019.09.058
dc.identifier.urihttps://rde.dspace-express.com/handle/11287/621222
dc.description.abstractAlthough cisplatin-fluoropyrimidine-based definitive chemoradiotherapy (dCRT) is a standard of care for oesophageal cancer, toxicity is significant and limits its use in elderly and frail patients. Weekly carboplatin-paclitaxel-based dCRT provides a viable alternative, although prospective data are lacking in the dCRT setting. Here we report the results of a national, multicentre retrospective review of outcome in patients treated with weekly carboplatin-paclitaxel-based dCRT.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.urlhttps://linkinghub.elsevier.com/retrieve/pii/S0936-6555(19)30439-Xen_US
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.en_US
dc.titleOutcome of weekly carboplatin-paclitaxel-based definitive chemoradiation in oesophageal cancer in patients not considered to be suitable for platinum-fluoropyrimidine-based treatment: a multicentre, retrospective reviewen_US
dc.typeJournal Articleen_US
dc.typeMulticenter Studyen_US
dc.identifier.journalClinical Oncologyen_US
dc.type.versionPublisheden_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record